The promises and challenges of using gene mutations for patient stratification in follicular lymphoma
Follicular lymphoma (FL) is a clinically and molecularly highly heterogeneous disease. Most patients achieve long-lasting remissions and have excellent overall survival (OS) with current treatment. However, ∼20% of patients have early progression of disease and short OS. At present, therapies are no...
Gespeichert in:
| Veröffentlicht in: | Blood Jg. 130; H. 13; S. 1491 - 1498 |
|---|---|
| Hauptverfasser: | , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
United States
American Society of Hematology
28.09.2017
|
| Schlagworte: | |
| ISSN: | 0006-4971, 1528-0020, 1528-0020 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Follicular lymphoma (FL) is a clinically and molecularly highly heterogeneous disease. Most patients achieve long-lasting remissions and have excellent overall survival (OS) with current treatment. However, ∼20% of patients have early progression of disease and short OS. At present, therapies are not guided by individual risk or disease biology. Reliable tools for patient stratification are urgently needed to avoid overtreatment of low-risk patients and to prioritize alternative approaches in high-risk patients. A rapidly expanding repertoire of promising therapeutic options is available for clinical evaluation; however, the numbers of patients with FL and the resources to conduct adequately powered trials are limited. Recent studies have shown that gene mutations can serve as prognostic and/or predictive biomarkers, in particular when integrated into composite risk models. Before translating these findings into routine clinical practice, however, several challenges loom. We review aspects of "clinicogenetic" risk model development and validation that apply to FL and more generally to other cancers. Finally, we propose a crowdsourcing effort that could expedite the development, validation, refinement, and selection of risk models. A new era of collaboration and harmonization is required if we hope to transition from empiric selection of therapeutics to risk-based, biology-guided treatment of patients with FL. |
|---|---|
| AbstractList | Follicular lymphoma (FL) is a clinically and molecularly highly heterogeneous disease. Most patients achieve long-lasting remissions and have excellent overall survival (OS) with current treatment. However, ∼20% of patients have early progression of disease and short OS. At present, therapies are not guided by individual risk or disease biology. Reliable tools for patient stratification are urgently needed to avoid overtreatment of low-risk patients and to prioritize alternative approaches in high-risk patients. A rapidly expanding repertoire of promising therapeutic options is available for clinical evaluation; however, the numbers of patients with FL and the resources to conduct adequately powered trials are limited. Recent studies have shown that gene mutations can serve as prognostic and/or predictive biomarkers, in particular when integrated into composite risk models. Before translating these findings into routine clinical practice, however, several challenges loom. We review aspects of "clinicogenetic" risk model development and validation that apply to FL and more generally to other cancers. Finally, we propose a crowdsourcing effort that could expedite the development, validation, refinement, and selection of risk models. A new era of collaboration and harmonization is required if we hope to transition from empiric selection of therapeutics to risk-based, biology-guided treatment of patients with FL.Follicular lymphoma (FL) is a clinically and molecularly highly heterogeneous disease. Most patients achieve long-lasting remissions and have excellent overall survival (OS) with current treatment. However, ∼20% of patients have early progression of disease and short OS. At present, therapies are not guided by individual risk or disease biology. Reliable tools for patient stratification are urgently needed to avoid overtreatment of low-risk patients and to prioritize alternative approaches in high-risk patients. A rapidly expanding repertoire of promising therapeutic options is available for clinical evaluation; however, the numbers of patients with FL and the resources to conduct adequately powered trials are limited. Recent studies have shown that gene mutations can serve as prognostic and/or predictive biomarkers, in particular when integrated into composite risk models. Before translating these findings into routine clinical practice, however, several challenges loom. We review aspects of "clinicogenetic" risk model development and validation that apply to FL and more generally to other cancers. Finally, we propose a crowdsourcing effort that could expedite the development, validation, refinement, and selection of risk models. A new era of collaboration and harmonization is required if we hope to transition from empiric selection of therapeutics to risk-based, biology-guided treatment of patients with FL. Follicular lymphoma (FL) is a clinically and molecularly highly heterogeneous disease. Most patients achieve long-lasting remissions and have excellent overall survival (OS) with current treatment. However, ∼20% of patients have early progression of disease and short OS. At present, therapies are not guided by individual risk or disease biology. Reliable tools for patient stratification are urgently needed to avoid overtreatment of low-risk patients and to prioritize alternative approaches in high-risk patients. A rapidly expanding repertoire of promising therapeutic options is available for clinical evaluation; however, the numbers of patients with FL and the resources to conduct adequately powered trials are limited. Recent studies have shown that gene mutations can serve as prognostic and/or predictive biomarkers, in particular when integrated into composite risk models. Before translating these findings into routine clinical practice, however, several challenges loom. We review aspects of "clinicogenetic" risk model development and validation that apply to FL and more generally to other cancers. Finally, we propose a crowdsourcing effort that could expedite the development, validation, refinement, and selection of risk models. A new era of collaboration and harmonization is required if we hope to transition from empiric selection of therapeutics to risk-based, biology-guided treatment of patients with FL. |
| Author | Oliver Weigert David M. Weinstock |
| Author_xml | – sequence: 1 givenname: Oliver orcidid: 0000-0002-0987-7373 surname: Weigert fullname: Weigert, Oliver organization: German Cancer Research Center, Heidelberg, Germany – sequence: 2 givenname: David M surname: Weinstock fullname: Weinstock, David M organization: Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA |
| BackLink | https://cir.nii.ac.jp/crid/1873961342251225728$$DView record in CiNii https://www.ncbi.nlm.nih.gov/pubmed/28784599$$D View this record in MEDLINE/PubMed |
| BookMark | eNo1kE1LxDAQhoMo7vrxD0Ry8OClOkmaJjmK-AWCFz2XNJ3uBtJkbdqD_97o6mFm3uF9GHjnhBzGFJGQCwY3jGl-24WU-ooDUxWoSgklpDggaya5rgA4HJI1ADRVbRRbkfOcfVd2rUxBj8mKa6Vracya4PsW6W5Ko8-YqY09dVsbAsZNWdNAl-zjhm4wIh2X2c4-xUyHNNFd0RhnmuepqMG7X4_6WNwQvFuCnWj4GnfbNNozcjTYkPH8b56Sj8eH9_vn6vXt6eX-7rVyEsRcdTX0qAcU0gLUcuh6LZwyfWMZNBxA9UJryZlTDQ4GXA3KmkahYdxaVjtxSq73d0uizwXz3JZcDkOwEdOSW2a4ElA3UhT08g9duhH7djf50U5f7f9rCnC1B6L3rfM_nWklTMNEzblkpRTX4hsBHXUh |
| CitedBy_id | crossref_primary_10_1016_S1470_2045_18_30339_5 crossref_primary_10_1038_s41408_020_00395_y crossref_primary_10_1002_hon_2674 crossref_primary_10_1111_bjh_15797 crossref_primary_10_1177_00368504251335082 crossref_primary_10_1182_bloodadvances_2023010779 crossref_primary_10_1007_s00761_019_0644_8 crossref_primary_10_1007_s15015_021_3433_3 crossref_primary_10_1016_j_annonc_2021_01_001 crossref_primary_10_1016_j_humpath_2019_08_019 crossref_primary_10_1016_j_blre_2021_100865 crossref_primary_10_1080_10428194_2023_2240462 crossref_primary_10_1182_blood_2017_11_764365 crossref_primary_10_1038_s41418_025_01445_3 crossref_primary_10_4049_jimmunol_1800137 crossref_primary_10_1016_S1470_2045_18_30114_1 crossref_primary_10_1007_s00428_019_02691_w crossref_primary_10_1007_s11864_018_0594_1 crossref_primary_10_1200_JCO_18_02365 crossref_primary_10_1038_s41375_022_01641_x |
| ContentType | Journal Article |
| Copyright | 2017 by The American Society of Hematology. |
| Copyright_xml | – notice: 2017 by The American Society of Hematology. |
| DBID | RYH CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1182/blood-2017-07-737353 |
| DatabaseName | CiNii Complete Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Chemistry Biology Anatomy & Physiology |
| EISSN | 1528-0020 |
| EndPage | 1498 |
| ExternalDocumentID | 28784599 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Review |
| GroupedDBID | --- -~X .55 0R~ 23N 2WC 34G 39C 4.4 53G 5GY 5RE 5VS 6J9 AAEDW AAXUO ABOCM ACGFO ACVFH ADBBV ADCNI ADVLN AENEX AEUPX AFPUW AIGII AITUG AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ BAWUL BTFSW CS3 DIK DU5 E3Z EBS EFKBS EJD EX3 F5P FDB FRP GS5 GX1 H13 IH2 K-O KQ8 L7B LSO MJL N9A OK1 P2P R.V RHI ROL RYH SJN THE TR2 TWZ W2D W8F WH7 WOQ WOW X7M YHG YKV AALRI AFETI AFOSN CGR CUY CVF ECM EIF NPM RHF 7X8 |
| ID | FETCH-LOGICAL-c503t-b40de8fe35a0045fbd83c79d6a1062007d388521c76ef90c407a967e912aa14c3 |
| ISICitedReferencesCount | 22 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000411886400003&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0006-4971 1528-0020 |
| IngestDate | Wed Oct 01 13:29:10 EDT 2025 Wed Feb 19 02:30:38 EST 2025 Mon Nov 10 09:08:07 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 13 |
| Language | English |
| License | 2017 by The American Society of Hematology. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c503t-b40de8fe35a0045fbd83c79d6a1062007d388521c76ef90c407a967e912aa14c3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| ORCID | 0000-0002-0987-7373 |
| OpenAccessLink | https://dx.doi.org/10.1182/blood-2017-07-737353 |
| PMID | 28784599 |
| PQID | 1927304653 |
| PQPubID | 23479 |
| PageCount | 8 |
| ParticipantIDs | proquest_miscellaneous_1927304653 pubmed_primary_28784599 nii_cinii_1873961342251225728 |
| PublicationCentury | 2000 |
| PublicationDate | 2017-09-28 20170928 |
| PublicationDateYYYYMMDD | 2017-09-28 |
| PublicationDate_xml | – month: 09 year: 2017 text: 2017-09-28 day: 28 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Blood |
| PublicationTitleAlternate | Blood |
| PublicationYear | 2017 |
| Publisher | American Society of Hematology |
| Publisher_xml | – name: American Society of Hematology |
| SSID | ssib000879737 ssib018463837 ssib001133653 ssib001235802 ssib000773200 ssib053239757 ssib003566298 ssib004261681 ssib058492389 ssib018734765 ssib000490011 ssib004644987 ssj0014325 |
| Score | 2.3637722 |
| SecondaryResourceType | review_article |
| Snippet | Follicular lymphoma (FL) is a clinically and molecularly highly heterogeneous disease. Most patients achieve long-lasting remissions and have excellent overall... |
| SourceID | proquest pubmed nii |
| SourceType | Aggregation Database Index Database Publisher |
| StartPage | 1491 |
| SubjectTerms | Biomarkers Humans Lymphoma, Follicular Lymphoma, Follicular - genetics Lymphoma, Follicular - pathology Mutation Prognosis Risk Assessment |
| Title | The promises and challenges of using gene mutations for patient stratification in follicular lymphoma |
| URI | https://cir.nii.ac.jp/crid/1873961342251225728 https://www.ncbi.nlm.nih.gov/pubmed/28784599 https://www.proquest.com/docview/1927304653 |
| Volume | 130 |
| WOSCitedRecordID | wos000411886400003&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1528-0020 dateEnd: 99991231 omitProxy: false ssIdentifier: ssib053239757 issn: 0006-4971 databaseCode: M~E dateStart: 0 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3Nb9MwFLfY-Lwg2PgosMlIiEsVSGwnzz6OaYhLyw5D9Fblw0FFXTqtLdou_O28F9tNKg0BBy5WYqlp6vfr8_vy7zH2Jhe5qSArokorEylts6hIU3RWgHgClTJgddtsAsZjPZmYU99tdNm2E4Cm0VdX5uK_ihrnUNh0dPYfxL15KE7gNQodRxQ7jn8teFSLKD_r-JfL0C-lrdpYt8EB_LQdnq9XvhCOag09w-rQEenWPpZH8ZCaiLtdver8GqW_8Lo85ILnvuF8YC2ohqN3w692hpbnotycBPo8pxIQmv9mfUbARxtwB6MEjO7wEdJIoaaUsg1ELtvlAIKizah5nYON9bqVyLBjEW8pX5-VceoT3bWktxXjrb5ZzWuijXWl_e4tIQIJMpU77LaA1JB-G_082cpv9jVZDCBFn5hQg4GeoZag694nnmtPFPeJ1tAKFqa_q2dJ1jvBq9DMNJ3hi2505kIB4R6kgi6_nEqBdmGXf0arEA1v6gPg82FKCteLwy-rPwSK6_D-plVAQ6mZzX7vNLXG09kj9tB7PfzIofUxu_U932P7Rw1K9Pyav-VtHXIr3D1290O4un8cuhHusXsjXwSyzywinAeEc0Q47xDOFzVvEc4J4XyDcI4I5x7hfBvhfNbwDuE8IPwJ-_Lx5Oz4U-S7hURlGstVVKi4srq2Ms3JT6mLSssSTJXlSZxRRL6SWqOxWkJmaxOXKobcZGBNIvI8UaV8ynabRWOfMw46NlWhLHkvqtDaFBp0asoiqUUu6nTADnB5p_ijcSRZGjSKlSBXAXdAoQfsdVj4Ka4FpeDyxi7Wyyn6U0C1CKkcsGdOItMLRyszFfglCqH74g9Pf8kedP_MV2x3dbm2B-xO-WM1W14esh2Y6MMW_TiOT0e_ALdopqs |
| linkProvider | ISSN International Centre |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+promises+and+challenges+of+using+gene+mutations+for+patient+stratification+in+follicular+lymphoma&rft.jtitle=Blood&rft.au=David+M.+Weinstock&rft.au=Oliver+Weigert&rft.date=2017-09-28&rft.pub=American+Society+of+Hematology&rft.issn=0006-4971&rft.eissn=1528-0020&rft.volume=130&rft.spage=1491&rft.epage=1498&rft_id=info:doi/10.1182%2Fblood-2017-07-737353 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0006-4971&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0006-4971&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0006-4971&client=summon |